NeoPro Pain Inc. (NPP) is a development company focusing on the discovery of novel pharmaceutical agents for pain. NPP is a wholly owned subsidiary of NeoPro Labs, LLC (NPL). NPP’s strategy is to complete the requirements of preclinical and clinical development for its drug candidate, EXIGAL™ that represents a new class of pain relief medication for pain. The company is seeking to form strategic alliances and partnerships.